

Capillary Collection Now Available

TM

Why choose OneTest Standard ?

OneTest Standard was our first innovative multi-cancer early detection (MCED) screening test that integrates well-established FDA approved biomarkers with cutting edge AI technology into our unique Lab Developed screening test known as OneTest. The results help provide a more advanced look at an individual's risk of being diagnosed with cancer over the following 12 months.

Fast Facts about Firefighter Cancer Screening

- Since 2002 The IAFF has attributed more LODD to Cancer. More than any other cause.
- According to the International Association of Fire Fighters, 72% of IAFF member line-of-duty deaths in 2023 were due to occupational cancer.
- Firefighters have a higher risk of contracting all forms of cancer. Higher than the general population
- OneTest reliably screens for more than 20 types of cancer at identifying more risk at stage 1 & 2, giving you the greatest opportunity to stay on top of rising health concerns.
- OneTest has 2 affordable & accessible solutions that fit your budget.
- OneTest gives you a Results Roadmap to show you what to do with your results when you receive them through our secure portal.



AFFORDABLE

CALL FOR DISCOUNTED PRICING

Requires a physician authorization as well as a blood draw. Both are available at time of purchase through our website. Capillary draw now available for even greater flexibility.



CONVENIENT

ONE TUBE – UP TO 7 MARKERS

SPECIFIED BY GENDER

With our patented AI algorithm for greater sensitivity and specificity

OneTest Standard™ screens for the following cancers:


Common

- Lung
- Liver
- Colon
- Prostate
- Kidney
- Pancreatic
- Ovarian
- Cervical
- Stomach
- Esophageal
- Breast

Less Common forms of Cancer

- Bladder
- Head & Neck
- Thyroid
- Leukemia
- Uterine
- Gallbladder
- Intra-hepatic
- Bile duct
- Parotid (salivary)
- Liposarcoma
- Sinonasal
- neuroendocrine
- Retroperitoneum
- Skin
- Testicular

Our Patented AI Algorithm is the secret to our increased Sensitivity and Accuracy



Important Note:

The results provided by **OneTest Premium** serve as a risk predictor and are not diagnostic for cancer. It is crucial that follow-up actions be determined by a healthcare professional who has access to the individual patient's complete health history. Biomarkers may register elevated levels for reasons unrelated to cancer, emphasizing the importance of professional interpretation and follow up.

It is essential to note that **OneTest Premium** is intended to be used by asymptomatic individuals and has not been designed for monitoring disease recurrence.

OneTest Premium is a Laboratory developed test (LDT) and has not yet received FDA approval.

For information



Screening for Cancer **OneTest**™ at a time
www.onetestforcancer.com





Why choose OneTest Premium™?


OneTest Premium™ is an innovative multi-cancer early detection (MCED) blood test that integrates well-established FDA approved biomarkers along with cutting edge AI technology into our unique Laboratory Developed Test (LDT). Providing a more advanced look at an individual's risk of being identified with 8 of the most prevalent cancer types over the following 12 months. (**Breast, Colon, Liver, Lung, Ovarian, Pancreatic, Prostate, and Stomach**)



AFFORDABLE

CALL FOR DISCOUNTED PRICING

- Requires a physician authorization as well as a blood draw. Both are available at time of purchase through our website.



Bar graph prepared by NCI's CSRN team in May 2024.
Effective specificity of OneTest by NCI estimated @ ~95%.



CONVENIENT

ONE TUBE - 12 MARKERS - 8 ALGORITHMS

One tube tests 12 markers for 8 of the most common cancers with more precise screening.

OneTest is believed to be more sensitive for many earlier-stage cancers than **Galleri**.

"Sensitivity of Grail's Galleri is only 27.5% for early-stage cancer (stage 1-2)... based on performance in patients with symptomatic disease and is likely to overestimate the screening performance." [The Lancet Feb. 3, 2024](https://www.thelancet.com/journals/langreen/article/101873).

OneTest Premium™ is TWO tests in ONE.
You get 2 sets of results for more information to help guide you.

OneTest Premium™ measures a panel of 12 markers:

Cancer

- AFP (Liver, testicular & ovarian)
- CA-125 (Ovarian & lung)
- CA 19-9 (Pancreatic, liver & GI)
- CEA (Lung, pancreatic & GI)
- CYFRA 21-1 (Lung, head/neck & breast)
- CA 15-3 (Breast--Female)
or TPSA (Prostate--male)
- HE4 (Ovarian)

Inflammatory

- Apo A1
- B2 Microglobulin
- Prealbumin
- CRP

Premium's Algorithms refine your risk down to 8 common cancer types

- Breast
- Colon
- Liver
- Lungs
- Ovarian
- Pancreatic
- Prostate
- Stomach

We make follow-up simple with our Results Roadmap

OneTest utilizes FDA approved biomarkers which makes follow-up easier through your insurance. Combine with the guidance provided in our Results Roadmap, continued diligence and rescreening becomes easy. Should you receive an elevated result, we provide you with the resources you can share with your physician to for you to be able to receive additional imaging or diagnostics through your insurance provider.

Let us design a custom testing protocol for your organization



OneTest™ Making Screening Easier

COPYRIGHT © 2025 | ONETEST- Screening for Cancer OneTest at a Time | ALL RIGHTS RESERVED.

